KYMR - Kymera Therapeutics, Inc.
83.52
-2.590 -3.101%
Share volume: 1,044,442
Last Updated: 03-05-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
-0.04%
PREVIOUS CLOSE
CHG
CHG%
$86.11
-2.59
-0.03%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-02-2024 | 08-07-2024 | 10-31-2024 | 02-27-2025 | 05-09-2025 | 11-04-2025 | 02-26-2026 | |
| Assets | ||||||||
| Total Assets | 868.251 M | 826.021 M | 1.035 B | 978.035 M | 918.312 M | 1.102 B | 1.743 B | |
| Current Assets | 537.253 M | 525.407 M | 568.715 M | 510.268 M | 500.951 M | 528.298 M | 871.214 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 2.030 M | 1.704 M | 1.317 M | 947.000 K | 20.000 M | 0.000 | 0.000 | |
| Short Term Investments | 427.034 M | 442.341 M | 439.252 M | 368.488 M | 373.184 M | 392.733 M | 491.265 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 93.510 M | 67.612 M | 110.718 M | 120.256 M | 89.966 M | 112.949 M | 357.011 M | |
| Total Non-current Assets | 224.390 M | 192.445 M | 361.035 M | 362.159 M | 312.335 M | 473.055 M | 771.158 M | |
| Property Plant Equipment | 49.336 M | 51.735 M | 51.244 M | 50.457 M | 49.172 M | 45.128 M | 43.175 M | |
| Other Assets | 281.662 M | 248.879 M | 414.883 M | 417.310 M | 368.189 M | 528.618 M | 828.423 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 868.251 M | 826.021 M | 1.035 B | 978.035 M | 918.312 M | 1.102 B | 1.743 B | |
| Total liabilities | 157.048 M | 141.097 M | 141.912 M | 142.416 M | 132.079 M | 155.786 M | 163.148 M | |
| Total current liabilities | 56.136 M | 62.143 M | 66.532 M | 67.767 M | 58.989 M | 71.575 M | 83.212 M | |
| Accounts Payable | 6.812 M | 6.510 M | 6.494 M | 5.989 M | 10.263 M | 5.506 M | 4.015 M | |
| Other liabilities | 77.131 M | 75.765 M | 75.380 M | 74.649 M | 73.090 M | 70.254 M | 68.496 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 77.131 M | 75.765 M | 75.380 M | 74.649 M | 73.090 M | 70.254 M | 68.496 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 711.203 M | 684.924 M | 892.930 M | 835.619 M | 786.233 M | 946.258 M | 1.580 B | |
| Common stock | 1.292 B | 1.308 B | 1.575 B | 1.592 B | 1.606 B | 1.924 B | 2.644 B | |
| Retained earnings | -579.309 M | -621.371 M | -683.858 M | -754.610 M | -820.191 M | -978.980 M | -1.066 B |